NCT00761449已完成2 期
A Multicentre Phase II Study of the Efficacy and Safety of Lenalidomide in High-risk Myeloid Disease (High-risk MDS and AML) With a Karyotype Including Del(5q) or Monosomy 5
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 18
- 主要终点
- Major cytogenetic response (50% or more reduction of the del5(q) or monosomy 5 FISH positive clone in the bone marrow using the LSI EGR1/D5S23,D5S721 FISH probe) after 16 weeks of lenalidomide treatment
研究概览
简要总结
The aim of this study is to investigate the efficacy of lenalidomide in high risk MDS or AML with chromosome 5 aberrations.
详细描述
Previous studies have shown that the immunomodulatory drug lenalidomide is effective in the treatment of low risk MDS with del(5q). Treatment of this subgroup of MDS patients resulted in 67% major erythroid responses and 45% complete cytogenetic responses. We therefore intend to test the efficacy of lenalidomide in a group of high-risk patients who are ineligible for conventional chemotherapy and who have a dismal prognosis. The patients must have a karyotype including del(5q) but patients with a karyotype including monosomy 5 are also eligible. We hypothesize that hight risk MDS or AML patients with other chromosomal aberrations than del(5q) can be affected by the lenalidomide effect.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be >18 years of age at the time of signing the informed consent form
- •MDS at IPSS Int-2 or High with a karyotype including del(5q) or monosomy 5 confirmed with FISH (using the LSI EGR1/D5S23,D5S721 FISH probe)
- •Acute myeloid leukemia with a karyotype including del(5q) or monosomy 5 confirmed with FISH (using the LSI EGR1/D5S23,D5S721 FISH probe)
- •Patients could be included if:
- •At diagnosis and not considered eligible for induction chemotherapy
- •Refractory to induction therapy
- •Relapse after induction chemotherapy leading to CR and considered not eligible for reinduction
- •Relapse after allogeneic stem cell transplantation and not considered suitable for reinduction chemotherapy or other conventional relapse therapy.
- •Subject has signed the informed consent document.
- •Women of childbearing potential, WCBP, must agree to practice complete abstinence from heterosexual intercourse or to use two methods of contraception beginning 4 weeks prior to the start of the study medication, while on study medication and 4 weeks after the last dose of study medication. WCBP must have two negative serum or urine pregnancy tests prior to starting study drug. WCBP must agree to have pregnancy tests weekly for the first 4 weeks and then every 4 weeks while on study medication and 4 weeks after the last dose of study medication.
- •Males (including those who have had a vasectomy) must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with WCBP while on study medication and 4 weeks after the last dose of study medication.
排除标准
- •Pregnant or lactating females.
- •Prior therapy with lenalidomide
- •Patients who are eligible for curative treatment
- •Expected survival less than two months.
- •Acute promyelocytic leukemia (APL)
- •Absolute peripheral blast count >30,000/mm3
- •Central nervous system leukemia
- •Serum biochemical values as follows
- •Serum creatinine >2.0 mg/dL (177 micromol/L)
- •Serum aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) >3.0 x upper limit of normal (ULN)
- •Serum total bilirubin >1.5 mg/dL (26 micromol/L)
- •Prior allergic reaction to thalidomide
- •Uncontrolled systemic infection
研究组 & 干预措施
1
Experimental
- lenalidomide
干预措施: lenalidomide (Drug)
结局指标
主要结局
Major cytogenetic response (50% or more reduction of the del5(q) or monosomy 5 FISH positive clone in the bone marrow using the LSI EGR1/D5S23,D5S721 FISH probe) after 16 weeks of lenalidomide treatment
时间窗: 16 weeks
次要结局
- Minor and complete cytogenetic (FISH) response after 8 and 16 weeks(16 weeks)
- Red blood cell transfusion independence(16 weeks)
- Erythroid response(16 weeks)
- Bone marrow response (morphology)(16 weeks)
- Modification of gene expression profiling during treatment(16 weeks)
- Safety(16 weeks)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
1 期
Study of Lenalidomide in Relapse/Refractory Waldenstrom MacroglobulinemiaWaldenstrom MacroglobulinemiaNCT02302469University Hospital, Lille17
终止
2 期
Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage DysplasiaMyelodysplastic SyndromeNCT00867308Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins32
已完成
2 期
Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5qMyelodysplastic SyndromesNCT01081431Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH91
已完成
2 期
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaNCT00799513IRCCS San Raffaele48
终止
1 期
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma Grade III (FL III°)Mantle Cell Lymphoma (MCL), Blastoid VariantBurkitt Lymphoma (BL)Aggressive Marginal Zone Lymphoma (MZL)NCT02983097Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH34